Key result
Guizhigancao Decoction improves cardiac function similarly to trimetazidine in rat heart failure models.
Why the study?
Heart failure mechanisms remain largely elusive and effective treatments are incompletely understood, necessitating the development of effective therapeutic strategies.
Does Guizhigancao Decoction improve cardiac function and reverse pathological remodeling in an induced rat model of heart failure?
Does Guizhigancao Decoction improve cardiac function and reverse pathological remodeling in an induced rat model of heart failure?
Answers are grounded in this paper and cite their sources.
GZGCD exerts a cardioprotective effect in experimental heart failure comparable to trimetazidine, which may be mediated by quercetin acting through oxidative response-related pathways.
Background and aim: HF (Heart Failure) is the leading cause of mortality and is a significant clinical problem affecting millions of patients worldwide. To date, the mechanisms of HF remain largely elusive. The effective treatments contributing to HF remain incompletely understood. Therefore, the development of an effective strategy for HF is urgently needed. Experimental procedure: . An integrative approach combining biomarker examination, echocardiography, myocardial fibrosis and cardiac apoptosis condition using Masson and TUNEL staining was performed to assess the efficacy of GZGCD against HF. Subsequently, comprehensive network pharmacology analyses were performed to explore the mechanisms involved in GZGCD therapeutic effects on HF. Results and conclusions: The results showed that GZGCD could reverse cardiac function in rats with HF by reducing NT-proBNP, increasing EF, decreasing LVESV, LVEDV, LVIDs, LVIDd, increasing running time, and ameliorate myocardial collagen fiber hyperplasia and cardiomyocyte apoptosis. We showed that GZGCD might contribute to HF treatment via oxidative related pathways through bioinformatics. Eventually, promising compound quercetin in GZGCD for HF therapeutics was proposed in database-based analysis. Collectively, our findings indicate that GZGCD has a treatment effect on HF. We proposed that GZGCD might contribute HF treatment via oxidative response-related pathways.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2023) studied Heart Failure (n=50). Guizhigancao Decoction (GZGCD) vs. Distilled water (HF control) and Trimetazidine 10 mg/kg daily (active positive control) was evaluated on Cardiac function (EF, NT-proBNP, LVESV, LVEDV, LVIDs, LVIDd) (p=<0.05). Guizhigancao Decoction reversed cardiac function in rats with heart failure by reducing NT-proBNP and improving echocardiographic parameters to a similar degree as trimetazidine.
Synapse has enriched 10 related papers. Consider them for comparative context: